Drug Discovery/Development meetings & conferences

International Conference on Natural Products and Health--NPH 2013

September 5-7, 2013 School of Biological Sciences, Nanyang Technological University, Singapore

NPH 2013 aims to bring together scientists and clinicians from academia, industry, hospitals and government laboratories to present new results and identify future research directions and therapeutic targets in natural products, drug discovery and medicine. The conference will be taking place on September 5-7, 2013 at the School of Biological Sciences (SBS), Nanyang Technological University (NTU) of Singapore.

With its unique focus and format, the conference provides participants updated information on the most recent and exciting developments in the field of natural products and health. It will examine current practices and advances of promising new generation of small molecules, peptides and protein biologics from plants and animals. Their impact on western and eastern medicine and healthcare will also be determined in the conference.

The NPH2013 is designed to stimulate the creation, discussion and exploration of innovative and inspirational research topics in food science, drug discovery, medicine, natural products and health.

Contact us

School of Biological Sciences
Divison of Structural Biology and Biochemistry
SBS-03S-74, Nanyang Technological University,
60 Nanyang Drive, Singapore, 637551
Phone: (65) 6316 7042
Email: nph2013@ntu.edu.sg

The Microbiome in Health, Disease, and Therapeutics: Bugs, Guts and Drugs

Friday, October 4, 2013 8:30 AM - 4:30 PM The New York Academy of Sciences New York, New York

Presented by the Biochemical Pharmacology Discussion Group

The host of microorganisms inhabiting the human body, or microbiome, plays essential roles in both health and the pathogenesis and resolution of disease. Symbioses between humans and the microbiome influence broad aspects of human biology including nutrition, immune function, and even brain development. Altered microbial community profiles are associated with a variety of chronic diseases such as inflammatory bowel disease, allergic conditions, obesity, and psychiatric and neurological disorders. The microbiome influences therapeutic interventions: metabolism of drugs by both intestinal bacteria and enterocytes, leading to systemic absorption may provide valuable insights into pre-systemic drug metabolism, delivery, and toxicity. A better understanding of the metabolic pathways may aid in drug development and toxicity evaluation processes. The microbiome itself may be a target of, or tool for new therapeutic strategies for diseases as diverse as irritable bowel syndrome, and Parkinson’s disease. This symposium reviews the basic biology of the human microbiome symbiosis and its systemic effects, the impact of the gut microbiome on drug metabolism, the opportunities offered by the microbiome for new drug development, and the essential role played by the microbiome in a variety of disease states.

12th International Workshop on Data Mining in Bioinformatics (BIOKDD '13)

In conjunction with the 19th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD'13)

August 11, 2013 Chicago, Illinois

The goal of this workshop is to encourage KDD researchers to take on the numerous challenges that Bioinformatics offers. This year, the workshop will feature the theme of building network and predictive models of biological processes and diseases using complex data. This field focuses on the use of computational approaches, especially from data mining and machine learning, and the large amount and variety of biological data being generated. The goal here is to build accurate predictive or descriptive network models of biological processes and diseases. These approaches have revolutionized the new age biology by enabling novel discoveries in basic biology and diseases like cancer and diabetes, as well as the development of therapeutics.

1st Annual International Conference on Pharmacology and Pharmaceutical Sciences (PHARMA 2013)

November 18-19, 2013 Bangkok, Thailand

The conference aims to explore pharmacology, its relation with pharmaceutical sciences and application in the development of healthcare products.

Through sharing and networking, PHARMA 2013 will provide an opportunity for researchers, practitioners and educators to exchange research evidence, practical experiences and innovative ideas on issues related to pharmacology and pharmaceutical sciences.

CONTACT US

PHARMA CONFERENCE SECRETARIAT
Global Science & Technology Forum (GSTF)
10 Anson Road, International Plaza,
Singapore 079903
DID : +65 6327 0166
Fax : +65 6327 0162

For General Enquiries info@pharma-conf.org

Global Health 2013, The Second International Conference on Global Health Challenges

November 17 - 22, 2013 - Lisbon, Portugal

Colocated with other events part of DataSys 2013

Tracks:

FUNDAMENTALS
Foundations in global health informatics; Computational health; Software for health; Independent living technologies; ICT and health; Platform interoperability; Semantic interoperability; Diagnosis systems; Applied health informatics; User interfaces and visualization

TECHNOLOGY
Bio-medical semantics; Bio-medicine; Disease biomarker prediction; Applications of bio-nano technology; Body networks; Mobile healthcare; Ubiquitous healthcare

TRENDS
Clinical epigenetic; Long term health conditions; Ambient assisted; Genetics; Virtual reality in medicine surgery; Clinical trials; Computational and knowledge management on proteomics and genomics; Drug design, disease diagnosis and control

PRACTICE
Nursing; Patient-centered care; Personalized medicine; Pervasive health; Homecare; Pharmaceutical services

ALTERNATIVE
Biomedicine; Natural medicine; Preventive medicine; Chronic diseases following; Home surveillance

CHALLENGES
Security aspects and access control on medical data; Data management in pervasive context; Data quality assurance and provenance; Patient flow models in hospitals; Clinical data analysis; Information visualization of medical data

GLOBAL
eHealth initiatives; Social medicine; Health global accessibility; Epidemic spreading and control; Health Education; Providing health in remote areas; Decision support within healthcare; Ethical aspects in eHealth; Healthcare plans and patient benefits; Synchronization of federal regulations; Availability of medication; Community health services

Advances in Plasmodium vivax Malaria Research

May 28 - 29, 2013 Barcelona, Spain

Presented by The New York Academy of Sciences, the "la Caixa" Foundation, B-DEBATE, Barcelona Institute for Global Health (ISGlobal), and the Barcelona Centre for International Health Research (CRESIB)

Malaria accounts for approximately 250 million clinical cases and nearly 1 million deaths annually, mostly in children, in 109 countries. There has been growing evidence that Plasmodium vivax is the most widely distributed malaria parasite, responsible for a significant burden of global disease and accounting for the majority of malaria cases in Latin America and Asia. Despite the increasing awareness that the overall burden, economic impact, and severity of P. vivax disease have been underestimated, this species remains underrepresented in the scientific literature and professional fora.

This 2-day conference will convene a global community of researchers to discuss P. vivax molecular biology and genomics, host–parasite interactions, novel research techniques (e.g., 'omics) to overcome barriers to in vitro, in vivo, and clinical study of P. vivax; drug resistance and drug discovery; and recent clinical trial and in-field efforts in P. vivax prevention, treatment, control, and elimination.

CHI's 13th Annual Structure-Based Drug Design Conference

June 19-21, 2013 Boston, Massachusetts

At CHI/Bio-IT World's thirteenth annual Structure-Based Drug Design conference, you will hear about developments in insilico technology, as well as experimental approaches useful for accurately predicting and modeling the structures of proteins in structure-based drug design efforts. In addition, examples of successful applications of such technology approaches to genome-to-drug lead investigations will be addressed.

International Conference on Intelligent Biology and Medicine (ICIBM 2013)

August 11-13, 2013, Nashville, Tennessee

Bioinformatics, Systems Biology and Intelligent Computing are synergistic disciplines that hold great promise for the advancement of biomedical research and development through the design of intelligent systems to solve engineering practical problems as well as translational science problems. Research and development in these areas impact science and technology, and synergies among these disciplines provide enormous potential. The International Conference on Intelligent Biology and Medicine (ICIBM) aims to provide a forum for the cross-fertilization of ideas and promotion of interdisciplinary collaborations. Keeping these objectives in mind, ICIBM solicits original contributions in the following non-exclusive lists of areas.

Bioinformatics

Functional genomics, personalized medicine, genetics and genomics, multi-dimensional data integration, next generation sequencing analysis (including algorithms, tools and data analysis), microarray based data analysis, biomedical data analysis, bio-molecular and phylogenetic databases, bio-languages, interoperability in bio-databases, bio-ontology and data mining, identification and classification of genes, sequence search and alignment, protein structure prediction and molecular simulation, molecular evolution and phylogeny, proteomics, drug discovery, drug design, bioinformatics engineering, bio-data visualization, algorithms, modeling and simulation of bio-datasets, biomarker discovery, bio-imaging, signaling and computation.

Systems Biology

Modeling and simulation of biological processes, pathways, networks, regulatory networks, pipelines, mathematical and quantitative models of cellular and multi-cellular systems, emergence of properties in complex biological systems, methods to predict biological network behavior from incomplete information, statistical modeling of biological data, prediction and validation, synthetic biological systems, high performance bio-computing, self-organization in living systems (cells, organisms, swarms, ecosystems, etc.), platforms for computational modeling of living systems (parallel, distributed, and multi-resolution simulation methods), differential, discrete and/or stochastic modeling-language frameworks, applications of systems biology towards understanding disease mechanisms, pharmaceutical drug discovery and drug target validation.

Intelligent Computing

Machine learning, data mining, knowledge discovery, pattern recognition, natural langue processing, literature mining, semantic and ontology driven biological data analysis, neural computing, kernel methods, evolutionary computing, swarm intelligence and optimization, feature selection/extraction, ensemble methods, manifold learning theory, artificial life and artificial immune systems, technology to develop artificial components, systematization methodology for intelligent systems, and scientific principles related to artificial life. 

For general questions/inquiries, please email us at icibm.list@gmail.com.

Drug Discovery Re-Invented

The Conference will take place at the Hilton Scottsdale Resort & Villas Scottsdale, Arizona, USA , from October 16-19 2013. 

The conference will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. Speakers will cover new developments in medicinal chemistry, natural products, structure-based design, and screening technologies. They will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.

This conference is designed to attract the following attendees: medicinal, computational, and synthetic organic chemists; structural and screening biologists; research management and entrepreneurs; industrial and academic scientists.

Human Genomics and Personalized Medicine

Organized in collaboration with Knut and Alice Wallenberg Foundation and Science for Life Laboratory - Stockholm

June 17 - 21, 2013 Stockholm, Sweden

The Human Genomics and Personalized Medicine meeting will be co-chaired by Drs. Kelly A Frazer and Geoffrey Ginsburg who respectively are leaders in the field of human genomics and personalized medicine. We have selected a diverse set of speakers based on their expertise who we believe can present a balanced and complementary view of the field. The meeting will have eight sessions highlighting: 1. Breakthroughs in Genomic and Personalized Medicine; 2. Genomes and Biology; 3. Policy; 4. Advances and Challenges in the Field; 5. Pharmacogenomics; 6. Personalized Genomes; 7. Cancer Genomics and Applications; and 8. Translating Biomarkers to Personalized Medicine.

For the “Breakthroughs in Genomic and Personalized Medicine” session to be as timely as possible we have left two spots open with the goal of choosing speakers in 2012 closer to the time of the meeting. The Genomes and Biology session includes talks on the role of inherited variants, the epigenome and microbiomes in disease. For the Policy session we have chosen experts to discuss consumer expectations and economic drivers for Personalized Medicine. Advances and Challenges in the Field includes talks on the key regulatory issues, analysis of complex data sets, developing robust biorepositories and public access to large data sets being generated on funds from NIH and other agencies. The Pharmacogenomics session features leaders in the field who are actively working in bringing genomic targeted therapies to the clinic in a variety of diseases. For the Personalized Genomes session leading experts using whole genome sequences for clinical trials and diagnostics will present. The Cancer Genomics and Applications session includes a representative of The Cancer Genome Atlas NIH sponsored program, an industry talk on successful translation of a commercial genomics diagnostics and two targeted therapy talks, one of which is focused on cancer stem cells. The Translating Biomarkers to Personalized Medicine session has three individuals from industry utilizing genome sequence data to develop diagnostics and for drug discovery. Finally, The Future of Genomic Medicine, a keynote address given by a leading government official who will discuss science and science policy with an emphasis on what the government doing to advance Personalized Health Care.

Keystone Symposia
160 U. S. Highway 6, Suite 200
PO Box 1630
Silverthorne, CO 80498
www.keystonesymposia.org

Hours of operation: 7:30 am to 4:00 pm (Mountain Time Zone)

Attendee Services: Registration and Abstract Submission
David Sanchez
Phone: +1 (800) 253-0685 or +1 (970) 262-1230
Fax: +1 (970) 262-1525